Table 3.
N | MXF (mg/L) | PIP/TAZ (mg/L) | AMC (mg/L) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | Range | ||
Staphylococcus aureus | ||||||||||
Methicillin-susceptible | 125 | 0.03 | 0.06 | ≤0.015–4.0 | 1.0 | 2.0 | 0.5–2.0 | 0.50 | 1.0 | ≤0.06–2.0 |
Methicillin-resistant | 27 | 2.0 | 8.0 | 0.12–8.0 | 16.0 | >128 | 4.0 to >128 | 8.0 | >32.0 | 2.0 to >32.0 |
Enterococcus faecalis | 67 | 0.25 | 16.0 | 0.12–16.0 | 4.0 | 8.0 | 2.0 to >128 | 1.0 | 1.0 | 0.25–32.0 |
Escherichia coli | ||||||||||
Non-ESBL-producing | 20 | 0.03 | 32.0 | 0.03 to >32.0 | 2.0 | 2.0 | 0.5–2.0 | 4.0 | 8.0 | 2.0–8.0 |
Bacteroides fragilis | 10 | 0.5 | 2.0 | 0.5–4.0 | 0.25 | 0.5 | 0.12–1.0 | – | – | – |
ESBL extended-spectrum beta-lactamase, N total number of isolates, ITT intent-to-treat, MXF moxifloxacin, PIP/TAZ–AMC piperacillin/tazobactam–amoxicillin/clavulanic acid; Streptococcus pyogenes (n = 6): for MXF: MIC50 0.12, MIC90 0.25, range 0.12–0.25; for PIP/TAZ: MIC50 ≤0.25, MIC90 ≤0.25, range ≤0.25 to ≤0.25; for AMC: MIC50 ≤0.06, MIC90 ≤0.06, range ≤0.06 to ≤0.06; Escherichia coli ESBL-producing (n = 3): for MXF: MIC90 ≥32.0; for PIP/TAZ: MIC90 = 16.0; for AMC: MIC90 = 16.0